The markers to predict the response to neoadjuvant therapy in patients with rectal cancer

Jiang Shu mei; Hongjiang Yan; Linzhi Jin; Xue Dou; Dong Chen; Xiaoqing Xu; Hongliang Guo; Dianbin Mu; Renben Wang

doi:10.24297/jap.v7i1.1750

Authors

Jiang Shu mei Shandong Cancer Hospital and Institute, Jinan, China
Hongjiang Yan Shandong Cancer Hospital and Institute, Jinan, China
Linzhi Jin Shandong Cancer Hospital and Institute, Jinan, China
Xue Dou Shandong Cancer Hospital and Institute, Jinan, China
Dong Chen Shandong Cancer Hospital and Institute, Jinan, China
Xiaoqing Xu Shandong Cancer Hospital and Institute, Jinan, China
Hongliang Guo Shandong Cancer Hospital and Institute, Jinan, China
Dianbin Mu Shandong Cancer Hospital and Institute, Jinan, China
Renben Wang Shandong Cancer Hospital and Institute, Jinan, China

DOI:

https://doi.org/10.24297/jap.v7i1.1750

Keywords:

Rectal cancer, Carcinoembryonic antigen, proliferating cell nuclear antigenï¼›Neoadjuvant chemoradiation.

Abstract

Locally advanced rectal cancer is currently treated with preoperative radiochemotherapy, but the response is not uniform. Most patients benefit from preoperative CRT, however, a small proportion of a patient population is less likely to respond to the treatment. The purpose of this study was to measure neoadjuvant therapy combined with Ki-67 and VEGF expression in pretreatment biopsies and postoperative specimensï¼Œserum carcinoembryonic antigen (CEA) and CA19-9 level from patients with locally advanced rectal cancer receiving intensive neoadjuvant treatment and to correlate the findings with clinical outcome.